Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation.

doi:10.1200/JCO.2013.52.3381

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Sept 2014

Bejar Rafael, Stevenson Kristen E, Caughey Bennett, Lindsley R Coleman, Mar Brenton G, Stojanov Petar, Getz Gad, Steensma David P, Ritz Jerome, Soiffer Robert, Antin Joseph H, Alyea Edwin, Armand Philippe, Ho Vincent, Koreth John, Neuberg Donna, Cutler Corey S, Ebert Benjamin L

Abstract excerpt

PURPOSE: Recurrently mutated genes in myelodysplastic syndrome (MDS) are pathogenic drivers and powerfully associated with clinical phenotype and prognosis. Whether these types of mutations predict outcome after allogeneic hematopoietic stem-cell transplantation (HSCT) in patients with MDS is not known. PATIENTS AND METHODS: We used massively parallel sequencing to examine tumor samples collected from 87 patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Disease-Free Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hematopoietic Stem Cell Transplantation

Share to Myelodysplastic Syndromes

Share to Prognosis

Share to Transplantation, Autologous

Share to Transplantation Conditioning

Share to Treatment Outcome

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 25092778
DOI: 10.1200/JCO.2013.52.3381
PMCID: PMC4207878

Genes

TET2
ASXL1
RUNX1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation.PMID 25092778Read ↗

Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell TransplantationSemantic proximity Read ↗

Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation.Semantic proximity Read ↗

Genetic and Clinical Features in TP53-Mutated Patients With Myelodysplastic Neoplasms: A Retrospective Study Based on Next-Generation Sequencing Data.Semantic proximity Read ↗

TP53 and IDH2 Somatic Mutations Are Associated With Inferior Overall Survival After Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome.Semantic proximity Read ↗

Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia.Semantic proximity Read ↗

Allogeneic Hematopoietic Cell Transplantation Improves Outcome in Myelodysplastic Syndrome Across High-Risk Genetic Subgroups: Genetic Analysis of the Blood and Marrow Transplant Clinical Trials Network 1102 Study.Semantic proximity Read ↗

Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes.Semantic proximity Read ↗

Molecular taxonomy of myelodysplastic syndromes and its clinical implications.Semantic proximity Read ↗

SF3B1, RUNX1 and TP53 Mutations Significantly Impact the Outcome of Patients With Lower-Risk Myelodysplastic Syndrome.Semantic proximity Read ↗

Comparative outcome and prognostic factor analysis among MDS/AML patients with TP53 mutations, snps, and wild type.Semantic proximity Read ↗

Clinical outcomes and characteristics of patients with TP53-mutated myelodysplastic syndromes.Semantic proximity Read ↗

Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.